refers to drugs which antagonise
the action of aldosterone
at mineralocorticoid receptors
. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure
. Spironolactone, the first member of the class, is also used in the management of hyperaldosteronism
(including Conn's syndrome
) and female hirsutism
Mode of action
Aldosterone antagonists are, as the name suggests, receptor antagonists
at the mineralocorticoid receptor
. Antagonism of these receptors inhibits sodium
resorption in the collecting duct
of the nephron
in the kidneys. This interferes with sodium/potassium exchange, reducing urinary potassium excretion and weakly increasing water excretion (diuresis).
Their adjunctive use in congestive heart failure relates to their additive diuretic effect in combination with other drugs, reducing edema and decreasing the cardiac workload.
Members of this class in clinical use include: